. 2021 Dec 1;12:161. doi: 10.4103/ijpvm.IJPVM_405_20

Table 3.

Effect of curcumin supplementation on migraine symptoms and inflammatory markers

Variables	Measurement Period	Curcumin group n=22	Placebo group n=22	P
IL-6 (ng/dL)	Before	79.69±28	64.92±23.8	0.69^b
	after	73.98±27	64.91±23.6	0.041^c
	P ^a	0.454^a	0.99^a	-
CGRP (ng/dL)	Before	194.72±28	146±18	0.162^b
	after	150±22	154±17	<0.001^c
	P ^a	<0.001^a	0.139^a	-
SEVERITY (VAS score)	Before	7.59±0.19	7.18±0.2	0.153^b
	after	3.6±0.34	6.27±0.34	0.001^c
	P ^a	<0.001^a	0.002^a	-
FREQUENCY (per month)	Before	11.3±1.4	8±0.96	0.075^b
	after	6.6±1.1	7.2±0.88	0.052^c
	P ^a	0.014^a	0.051^a	-
DURATION (hours)	Before	21.8±4.07	24.45±3.8	0.639^b
	after	11.54±2.2	21.9±3.8	0.007^c
	P ^a	0.003^a	0.022^a	-

Data are presented as means±SE; P^a Result from paired samples t-test; P^b Result from independent t-test; P^c Result from Multivariate Analysis of Covariance (MANCOVA); Adjustment was made for pre-intervention values and energy intake. IL-6: Interleukin-6; CGRP: Calcitonin gene relating peptide; VAS: Visual Analogue Scale